7519-36-0

Basic information

• Product Name: N-NITROSO-L-PROLINE
• Synonyms: N-NITROSO-L-PROLINE;1-nitroso-l-proline;nitrosoproline;no-pro;N-NITROSO-PROLINE;1-Nitrosoproline;NPRO;L-Proline, 1-nitroso-
• CAS NO: 7519-36-0
• Molecular Formula: C₅H₈N₂O₃
• Molecular Weight: 144.13
• Product Categories: Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives;Heterocycles;Amino Acids & Derivatives, Heterocycles
• Mol File: 7519-36-0.mol

Chemical Properties

• Melting Point: 108-109°C
• Boiling Point: 262.71°C (rough estimate)
• Flash Point: 190.688oC
• Appearance: /
• Density: 1.4054 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.4472 (estimate)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly), Water (Sparingly, S
• PKA: 3.23±0.20(Predicted)
• CAS DataBase Reference: N-NITROSO-L-PROLINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-NITROSO-L-PROLINE(7519-36-0)
• EPA Substance Registry System: N-NITROSO-L-PROLINE(7519-36-0)

Safety Data

• Hazardous Substances Data: 7519-36-0(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Plates

Production Methods

There is no indication that nitrosoproline was made commercially. It has been reported in cured meats (e.g., bacon) at concentrations of 340–440 μg/kg. Both higher and lower levels in several cured products have been reported by several authors.

Safety Profile

Poison by intraperitoneal route.Questionable carcinogen with experimental tumorigenicdata. Many nitroso compounds are carcinogens. Whenheated to decomposition it emits toxic fumes of NOx. Seealso NITROSO COMPOUNDS.

Carcinogenicity

Mice were given 0.1% NPRO in drinking water for 26 weeks, and no more lung adenomas were seen than in untreated controls at 38 weeks, showing a lack of carcinogenicity. In rats, higher doses (0.145%) in drinking water for 2 years showed no tumors that were not seen in untreated controls (174). IARC classified NPRO as not classifiable as to carcinogenicity to humans (Group 3).

InChI:InChI=1/C5H8N2O3/c8-5(9)4-2-1-3-7(4)6-10/h4H,1-3H2,(H,8,9)/t4-/m0/s1

Upstream product

• 147-85-3 L-proline 
• 70-34-8 2,4-Dinitrofluorobenzene 

Downstream Products

• 147-85-3 L-proline 
• 98262-66-9 3a,4,5,6-tetrahydro-3-oxo-3H-pyrrolo[1,2-c][1,2,3]oxadiazol-7-ium ylide 
• 102608-17-3 N-trifluoroacetylamino-2-pyrrolidone 
• 604003-91-0 (S)-1-aminopyrrolidine-2-carboxylic acid methyl ester 
• 15265-22-2 L-aminopyrrolidine-2-carboxylic acid 
• 127221-89-0 (S)-(-)-1-amino-2-(hydroxymethyl)pyrrolidine 
• 71922-04-8 (S)-1-nitrosopyrrolidine-2-carboxylic acid methyl ester 

Relevant articles and documents

MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS

Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth

MACROCYCLIC INDOLES AS MCL-1 INHIBITORS

Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, ?, ?, ? are as defined as set forth in the specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

BENZOTRIAZOLE-DERIVED AND UNSATURATED AMIDE COMPOUND USED AS TGF- R1 INHIBITOR

A benzotriazole-derived α and β-unsaturated amide compound used as TGF-βR1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I).

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Prolinimines: N-Amino- l -Pro-methyl Ester (Hydrazine) Schiff Bases from a Fish Gastrointestinal Tract-Derived Fungus, Trichoderma sp. CMB-F563

A rice cultivation of a fish gastrointestinal tract-derived fungus, Trichoderma sp. CMB-F563, yielded natural products incorporating a rare hydrazine moiety, embedded within a Schiff base. Structures inclusive of absolute configurations were assigned to prolinimines A-D (1-4) on the basis of detailed spectroscopic and C3 Marfey's analysis, as well as biosynthetic considerations, biomimetic total synthesis, and chemical transformations. Of note, monomeric 1 proved to be acid labile and, during isolation, underwent quantitative transformation to dimeric 3 and trimeric 4. Prolinimines are only the second reported natural products incorporating an N-amino-Pro residue, the first to include l-Pro, the first to occur as Schiff bases, and the first to be isolated from a microorganism.

FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

N-nitrosation of secondary amines using p-TSA-NaNO2 as a novel nitrosating agent under mild conditions

A combination of p-toluenesulfonic acid (p-TSA) and sodium nitrite was used as a novel effective nitrosating agent for the N-nitrosation of secondary amines to their corresponding nitroso derivatives under mild and heterogeneous conditions in moderate to excellent yields.

A divergent strategy to the withasomnines

A concise synthesis of three members of the withasomnine family of natural products is reported. The synthesis features a regioselective sydnone-alkynylboronate cycloaddition followed by Suzuki cross coupling and silyl group removal, and marks the first d

Stabilisation of peptide foldamers in an aqueous medium by incorporation of azapeptide building blocks

Stable foldamers in water: Helical peptidic foldamers including H12 and H10/12 helices were constructed and stabilised in water. The foldamers' extra rigidity stems from the strong hydrogen bonding network of the azapeptide groups (see graphic).

Efficient procedure for chemoselective N-nitrosation of secondary amines with trichloromelamine-NaNO2

A combination of trichloromelamine and sodium nitrite in the presence of wet silica gel was used as an effective nitrosating agent for the transformation of secondary amines into the corresponding N-nitroso derivatives under mild and heterogeneous conditions in good to excellent yields.